Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Vaccines

  Free Subscription


01.01.2017

1 AIDS
3 AIDS Res Hum Retroviruses
1 BMJ
3 Clin Infect Dis
1 J Immunol
7 J Infect Dis
2 J Virol
1 JAMA
5 Lancet
1 Lancet Glob Health
8 Lancet Infect Dis
1 Lancet Oncol
1 MMWR Morb Mortal Wkly Rep
1 Nat Med
8 Pediatr Infect Dis J
1 Pediatrics
8 PLoS One
2 Proc Natl Acad Sci U S A
1 Science
39 Vaccine


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AIDS

  1. HARPER KN
    New mouse models provide insights into how to design a more effective HIV vaccine.
    AIDS. 2016 Dec 19. doi: 10.1097/QAD.0000000000001371.
    PubMed     Text format    


    AIDS Res Hum Retroviruses

  2. JOACHIM A, Munseri PJ, Nilsson C, Bakari M, et al
    Three-year durability of immune responses induced by HIV-DNA and HIV-modified vaccinia virus Ankara and effect of a late HIV-MVA boost in Tanzanian volunteers.
    AIDS Res Hum Retroviruses. 2016 Dec 27. doi: 10.1089/AID.2016.0251.
    PubMed     Text format     Abstract available

  3. KARPENKO LI, Lebedev LR, Bazhan SI, Korneev DV, et al
    Visualization of CombiHIVvac Vaccine Particles Using Electron Microscopy.
    AIDS Res Hum Retroviruses. 2016.
    PubMed     Text format    

  4. KARNASUTA C, Akapirat S, Madnote S, Savadsuk H, et al
    Comparison of Antibody Responses Induced by RV144, VAX003 and VAX004 Vaccination Regimens.
    AIDS Res Hum Retroviruses. 2016 Dec 22. doi: 10.1089/AID.2016.0204.
    PubMed     Text format     Abstract available


    BMJ

  5. KMIETOWICZ Z
    Ebola vaccine is highly protective, show latest study results.
    BMJ. 2016;355:i6842.
    PubMed     Text format    


    Clin Infect Dis

  6. TATE JE, Burton AH, Boschi-Pinto C, Parashar UD, et al
    Global, Regional, and National Estimates of Rotavirus Mortality in Children <5 Years of Age, 2000-2013.
    Clin Infect Dis. 2016;62 Suppl 2:S96-S105.
    PubMed     Text format     Abstract available

  7. LIN A, Ong KJ, Hobbelen P, King E, et al
    Impact and cost-effectiveness of selective human papillomavirus vaccination of men who have sex with men.
    Clin Infect Dis. 2016 Dec 23. pii: ciw845. doi: 10.1093.
    PubMed     Text format     Abstract available

  8. JAYASINGHE S, Menzies R, Chiu C, Toms C, et al
    Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    J Immunol

  9. SCHMIEL SE, Yang JA, Jenkins MK, Mueller DL, et al
    Cutting Edge: Adenosine A2a Receptor Signals Inhibit Germinal Center T Follicular Helper Cell Differentiation during the Primary Response to Vaccination.
    J Immunol. 2016 Dec 16. pii: 1601686.
    PubMed     Text format     Abstract available


    J Infect Dis

  10. DONKEN R, Schurink-van 't Klooster TM, Schepp RM, van der Klis FR, et al
    Immune responses after two- versus three-doses of HPV vaccination up to 4(1/2) years post vaccination: an observational study among Dutch routinely vaccinated girls (HPV2D).
    J Infect Dis. 2016 Dec 23. pii: jiw588. doi: 10.1093.
    PubMed     Text format     Abstract available

  11. HEARD I, Tondeur L, Arowas L, Demazoin M, et al
    Effectiveness of HPV vaccination on prevalence of vaccine genotypes in young sexually active women in France.
    J Infect Dis. 2016 Dec 23. pii: jiw639. doi: 10.1093.
    PubMed     Text format     Abstract available

  12. JOHN J, Giri S, Karthikeyan AS, Lata D, et al
    The duration of intestinal immunity after an inactivated poliovirus vaccine booster dose in children immunized with oral vaccine: a randomised controlled trial.
    J Infect Dis. 2016 Dec 21. pii: jiw595. doi: 10.1093.
    PubMed     Text format     Abstract available

  13. CHENG A, Chang SY, Sun HY, Tsai MS, et al
    Long-term durability of responses to 2 or 3 doses of hepatitis A vaccination in HIV-positive adults on antiretroviral therapy.
    J Infect Dis. 2016 Dec 23. pii: jiw605. doi: 10.1093.
    PubMed     Text format     Abstract available

  14. MANOR Y, Lewis M, Ram D, Daudi N, et al
    Evidence for Hepatitis A virus endemic circulation in Israel despite universal toddlers' vaccination since 1999 and low clinical incidence in all age groups.
    J Infect Dis. 2016 Dec 23. pii: jiw611. doi: 10.1093.
    PubMed     Text format     Abstract available

  15. TRIEU MC, Zhou F, Lartey S, Jul-Larsen A, et al
    Long-term maintenance of the influenza-specific cross-reactive memory CD4+ T-cell responses following repeated annual influenza vaccination.
    J Infect Dis. 2016 Dec 22. pii: jiw619. doi: 10.1093.
    PubMed     Text format     Abstract available

  16. MOSLEY YC, Radder JE, Berndt A, HogenEsch H, et al
    Genome-Wide Association Mapping of the Antibody Response to Diphtheria-Tetanus-acellular Pertussis Vaccine in Mice.
    J Infect Dis. 2016 Dec 23. pii: jiw587. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Virol

  17. LEE J, Hashimoto M, Im SJ, Araki K, et al
    Adenovirus serotype 5 vaccination results in suboptimal CD4 T helper 1 responses in mice.
    J Virol. 2016 Dec 21. pii: JVI.01132-16. doi: 10.1128/JVI.01132.
    PubMed     Text format     Abstract available

  18. DAI A, Cao S, Dhungel P, Luan Y, et al
    Ribosome Profiling Reveals Translational Upregulation of Cellular Oxidative Phosphorylation mRNAs During Vaccinia Virus-induced Host Shutoff.
    J Virol. 2016 Dec 21. pii: JVI.01858-16. doi: 10.1128/JVI.01858.
    PubMed     Text format     Abstract available


    JAMA

  19. ABBASI J
    First Inactivated Zika Vaccine Trial.
    JAMA. 2016;316:2588.
    PubMed     Text format    


    Lancet

  20. HENAO-RESTREPO AM, Camacho A, Longini IM, Watson CH, et al
    Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!).
    Lancet. 2016 Dec 23. pii: S0140-6736(16)32621.
    PubMed     Text format     Abstract available

  21. GEISBERT TW
    First Ebola virus vaccine to protect human beings?
    Lancet. 2016 Dec 22. pii: S0140-6736(16)32618.
    PubMed     Text format    

  22. GROBUSCH MP, Goorhuis A
    Safety and immunogenicity of a recombinant adenovirus vector-based Ebola vaccine.
    Lancet. 2016 Dec 22. pii: S0140-6736(16)32619.
    PubMed     Text format    

  23. ZHU FC, Wurie AH, Hou LH, Liang Q, et al
    Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2016 Dec 22. pii: S0140-6736(16)32617.
    PubMed     Text format     Abstract available

  24. MASTERSON L, O'Mahony J, Lechner M
    Expanding the benefits of HPV vaccination to boys and men.
    Lancet. 2017;388:2992.
    PubMed     Text format    


    Lancet Glob Health

  25. LI JX, Hou LH, Meng FY, Wu SP, et al
    Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.
    Lancet Glob Health. 2016 Dec 22. pii: S2214-109X(16)30367.
    PubMed     Text format     Abstract available


    Lancet Infect Dis

  26. OTIENO TL, Otsyula N
    Questioning effectiveness of vaccines against malaria - Authors' reply.
    Lancet Infect Dis. 2017;17:22-23.
    PubMed     Text format    

  27. RAOULT D
    Questioning effectiveness of vaccines against malaria.
    Lancet Infect Dis. 2017;17:22.
    PubMed     Text format    

  28. PAN XF, Li R, Pan A, Larson H, et al
    Human papillomavirus vaccine approval in China: a major step forward but challenges ahead.
    Lancet Infect Dis. 2016;16:1322-1323.
    PubMed     Text format    

  29. UJIIE M, Sasaki K, Yoshikawa N, Enami T, et al
    Introduction of a hepatitis B vaccine into the national routine immunisation programme of Japan.
    Lancet Infect Dis. 2016;16:1325.
    PubMed     Text format    

  30. ATWELL JE, Karron RA
    Vaccination against respiratory syncytial virus in pregnancy.
    Lancet Infect Dis. 2016;16:1330-1331.
    PubMed     Text format    

  31. TUNLEY S
    Herd protection from the female HPV vaccination programme.
    Lancet Infect Dis. 2016;16:1333-1334.
    PubMed     Text format    

  32. BAGHI HB, Yousefi B, Oskouee MA, Aghazadeh M, et al
    HPV vaccinations: a Middle Eastern and north African dilemma.
    Lancet Infect Dis. 2017;17:18-19.
    PubMed     Text format    

  33. CHOW EP, Danielewski J, Fairley CK
    Herd protection from the female HPV vaccination programme - Authors' reply.
    Lancet Infect Dis. 2016;16:1334-1335.
    PubMed     Text format    


    Lancet Oncol

  34. BURKI TK
    Personalised vaccine against acute myeloid leukaemia.
    Lancet Oncol. 2016 Dec 15. pii: S1470-2045(16)30655.
    PubMed     Text format    


    MMWR Morb Mortal Wkly Rep

  35. WISEMAN R, Weil LM, Lozano C, Johnson TJ Jr, et al
    Notes from the Field: Health Care-Associated Hepatitis A Outbreak - Texas, 2015.
    MMWR Morb Mortal Wkly Rep. 2016;65:425-426.
    PubMed     Text format     Abstract available


    Nat Med

  36. ERASMUS JH, Auguste AJ, Kaelber JT, Luo H, et al
    A chikungunya fever vaccine utilizing an insect-specific virus platform.
    Nat Med. 2016 Dec 19. doi: 10.1038/nm.4253.
    PubMed     Text format     Abstract available


    Pediatr Infect Dis J

  37. KOSALARAKSA P, Watanaveeradej V, Pancharoen C, Capeding MR, et al
    Long-Term Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers and Booster Response 5 Years After Primary Immunization.
    Pediatr Infect Dis J. 2016 Dec 27. doi: 10.1097/INF.0000000000001494.
    PubMed     Text format     Abstract available

  38. GAENSBAUER JT, Asturias EJ, Soto M, Holt E, et al
    Pediatric Invasive Pneumococcal Disease in Guatemala City: Importance of Serotype 2.
    Pediatr Infect Dis J. 2016;35:e139-43.
    PubMed     Text format     Abstract available

  39. POYHONEN L, Pauniaho SL, Kroger L, Korppi M, et al
    Orthopedic Complications in Former Bacillus Calmette-Guerin Osteitis Patients.
    Pediatr Infect Dis J. 2016;35:579-80.
    PubMed     Text format     Abstract available

  40. MARCHISIO P, Esposito S, Picca M, Baggi E, et al
    Serotypes not Included in 13-Valent Pneumococcal Vaccine as Causes of Acute Otitis Media with Spontaneous Tympanic Membrane Perforation in a Geographic Area with High Vaccination Coverage.
    Pediatr Infect Dis J. 2016 Dec 15. doi: 10.1097/INF.0000000000001485.
    PubMed     Text format     Abstract available

  41. MERINO ARRIBAS JM, Carmona Martinez A, Horn M, Porcuna XM, et al
    Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Co-Administered with Routine Childhood Vaccines in European Infants: An Open, Randomized Trial.
    Pediatr Infect Dis J. 2016 Dec 19. doi: 10.1097/INF.0000000000001484.
    PubMed     Text format     Abstract available

  42. TRUCK J, Mitchell R, Jawad S, Clutterbuck EA, et al
    Divergent Memory B Cell Responses in a Mixed Infant Pneumococcal Conjugate Vaccine Schedule.
    Pediatr Infect Dis J. 2016 Dec 23. doi: 10.1097/INF.0000000000001497.
    PubMed     Text format     Abstract available

  43. DE WALS P, Zhou Z
    Cost-Effectiveness Comparison of Monovalent C Versus Quadrivalent ACWY Meningococcal Conjugate Vaccination in Canada.
    Pediatr Infect Dis J. 2016 Dec 23. doi: 10.1097/INF.0000000000001512.
    PubMed     Text format     Abstract available

  44. SIRIMA SB, Tiono A, Gansane Z, Siribie M, et al
    Immunogenicity and Safety Of 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Administered to Children with Sickle Cell Disease Between 8 Weeks and 2 Years of Age: A Phase III, Open, Controlled Study.
    Pediatr Infect Dis J. 2016 Dec 27. doi: 10.1097/INF.0000000000001518.
    PubMed     Text format     Abstract available


    Pediatrics

  45. TSENG HF, Sy LS, Ackerson BK, Hechter RC, et al
    Safety of Quadrivalent Meningococcal Conjugate Vaccine in 11- to 21-Year-Olds.
    Pediatrics. 2016 Dec 26. pii: e20162084. doi: 10.1542/peds.2016-2084.
    PubMed     Text format     Abstract available


    PLoS One

  46. WONG C, Jiang M, You JH
    Potential Cost-Effectiveness of an Influenza Vaccination Program Offering Microneedle Patch for Vaccine Delivery in Children.
    PLoS One. 2016;11:e0169030.
    PubMed     Text format     Abstract available

  47. LAMBKIN-WILLIAMS R, Gelder C, Broughton R, Mallett CP, et al
    An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Inf
    PLoS One. 2016;11:e0163089.
    PubMed     Text format     Abstract available

  48. TOTA JE, Jiang M, Ramanakumar AV, Walter SD, et al
    Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination.
    PLoS One. 2016;11:e0166329.
    PubMed     Text format     Abstract available


  49. Correction: A Prime-Boost Vaccination Strategy in Cattle to Prevent Foot-and-Mouth Disease Using a "Single-Cycle" Alphavirus Vector and Empty Capsid Particles.
    PLoS One. 2016;11:e0169025.
    PubMed     Text format     Abstract available

  50. MBUNDA T, Tarimo EA, Chalamilla G, Bakari M, et al
    The Influence of Community Members on Participation by Youth in an HIV Vaccine Trial in Tanzania.
    PLoS One. 2016;11:e0168660.
    PubMed     Text format     Abstract available

  51. SEDEGAH M, Peters B, Hollingdale MR, Ganeshan HD, et al
    Correction: Vaccine Strain-Specificity of Protective HLA-Restricted Class 1 P. falciparum Epitopes.
    PLoS One. 2016;11:e0168952.
    PubMed     Text format     Abstract available

  52. LAHEY T, Laddy D, Hill K, Schaeffer J, et al
    Immunogenicity and Protective Efficacy of the DAR-901 Booster Vaccine in a Murine Model of Tuberculosis.
    PLoS One. 2016;11:e0168521.
    PubMed     Text format     Abstract available

  53. ROSSI R, Assaad R, Rebeschini A, Hamadeh R, et al
    Vaccination Coverage Cluster Surveys in Middle Dreib - Akkar, Lebanon: Comparison of Vaccination Coverage in Children Aged 12-59 Months Pre- and Post-Vaccination Campaign.
    PLoS One. 2016;11:e0168145.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  54. WU CY, Lin CW, Tsai TI, Lee CD, et al
    Influenza A surface glycosylation and vaccine design.
    Proc Natl Acad Sci U S A. 2016 Dec 27. pii: 201617174.
    PubMed     Text format     Abstract available

  55. REBER SO, Siebler PH, Donner NC, Morton JT, et al
    Immunization with a heat-killed preparation of the environmental bacterium Mycobacterium vaccae promotes stress resilience in mice.
    Proc Natl Acad Sci U S A. 2016;113:E3130-9.
    PubMed     Text format     Abstract available


    Science

  56. NORMILE D
    Critics assail paper claiming harm from cancer vaccine.
    Science. 2016;354:1514-1515.
    PubMed     Text format    


    Vaccine

  57. DE BENEDETTO G, Alfini R, Cescutti P, Caboni M, et al
    Characterization of O-antigen delivered by Generalized Modules for Membrane Antigens (GMMA) vaccine candidates against nontyphoidal Salmonella.
    Vaccine. 2017;35:419-426.
    PubMed     Text format     Abstract available

  58. HOEST C, Seidman JC, Lee G, Platts-Mills JA, et al
    Vaccine coverage and adherence to EPI schedules in eight resource poor settings in the MAL-ED cohort study.
    Vaccine. 2017;35:443-451.
    PubMed     Text format     Abstract available

  59. THOMAS SL, Walker JL, Fenty J, Atkins KE, et al
    Impact of the national rotavirus vaccination programme on acute gastroenteritis in England and associated costs averted.
    Vaccine. 2016 Dec 19. pii: S0264-410X(16)31119.
    PubMed     Text format     Abstract available

  60. PEHRSON C, Heno KK, Adams Y, Resende M, et al
    Comparison of functional assays used in the clinical development of a placental malaria vaccine.
    Vaccine. 2016 Dec 21. pii: S0264-410X(16)31235.
    PubMed     Text format     Abstract available

  61. REYES M, Ramirez C, Nancucheo I, Villegas R, et al
    A novel "in-feed" delivery platform applied for oral DNA vaccination against IPNV enables high protection in Atlantic salmon (Salmon salar).
    Vaccine. 2016 Dec 21. pii: S0264-410X(16)31220.
    PubMed     Text format     Abstract available

  62. SHEN Z, Bowen RA, Ge P, Yu J, et al
    Evaluation of a candidate live attenuated influenza vaccine prepared in Changchun BCHT (China) for safety and efficacy in ferrets.
    Vaccine. 2016;34:5953-5958.
    PubMed     Text format     Abstract available

  63. KRASZEWSKA-G OMBA B, Matkowska-Kocjan A, Mi Kiewicz K, Szyma Ska-Toczek Z, et al
    Mumps, measles and rubella vaccination in children with PFAPA syndrome.
    Vaccine. 2016;34:5903-5906.
    PubMed     Text format     Abstract available

  64. KULKARNI SP, Thanapati S, Arankalle VA, Tripathy AS, et al
    Specific memory B cell response and participation of CD4+ central and effector memory T cells in mice immunized with liposome encapsulated recombinant NE protein based Hepatitis E vaccine candidate.
    Vaccine. 2016;34:5895-5902.
    PubMed     Text format     Abstract available

  65. LEON A, David AL, Madeline B, Guianvarc'h L, et al
    The EB66(R) cell line as a valuable cell substrate for MVA-based vaccines production.
    Vaccine. 2016;34:5878-5885.
    PubMed     Text format     Abstract available

  66. FUENTES S, Arenas D, Moore MM, Golding H, et al
    Development of bioluminescence imaging of respiratory syncytial virus (RSV) in virus-infected live mice and its use for evaluation of therapeutics and vaccines.
    Vaccine. 2016 Dec 15. pii: S0264-410X(16)31105.
    PubMed     Text format     Abstract available

  67. CHIU C
    Novel immunological insights in accelerating RSV vaccine development.
    Vaccine. 2017;35:459-460.
    PubMed     Text format    

  68. GARGANO LM, Hajjeh R, Cookson ST
    Pneumonia prevention: Cost-effectiveness analyses of two vaccines among refugee children aged under two years, Haemophilus influenzae type b-containing and pneumococcal conjugate vaccines, during a humanitarian emergency, Yida camp, South Sudan.
    Vaccine. 2017;35:435-442.
    PubMed     Text format     Abstract available

  69. SCHAEDLER E, Remy-Ziller C, Hortelano J, Kehrer N, et al
    Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors.
    Vaccine. 2016 Dec 21. pii: S0264-410X(16)31227.
    PubMed     Text format     Abstract available

  70. RISSMANN M, Ulrich R, Schroder C, Hammerschmidt B, et al
    Vaccination of alpacas against Rift Valley fever virus: Safety, immunogenicity and pathogenicity of MP-12 vaccine.
    Vaccine. 2016 Dec 21. pii: S0264-410X(16)31197.
    PubMed     Text format     Abstract available

  71. STANFIELD BA, Pahar B, Chouljenko VN, Veazey R, et al
    Vaccination of rhesus macaques with the live-attenuated HSV-1 vaccine VC2 stimulates the proliferation of mucosal T cells and germinal center responses resulting in sustained production of highly neutralizing antibodies.
    Vaccine. 2016 Dec 22. pii: S0264-410X(16)31225.
    PubMed     Text format     Abstract available

  72. RUNGE S, Olbert M, Herden C, Malberg S, et al
    Viral vector vaccines protect cockatiels from inflammatory lesions after heterologous parrot bornavirus 2 challenge infection.
    Vaccine. 2016 Dec 22. pii: S0264-410X(16)31229.
    PubMed     Text format     Abstract available

  73. TIMMIS JK, Rigat F, Rappuoli R
    Core values for vaccine evaluation.
    Vaccine. 2016 Dec 22. pii: S0264-410X(16)31082.
    PubMed     Text format     Abstract available

  74. EJIGU DA
    When should a time at risk start in efficacy malaria vaccine trials?
    Vaccine. 2017;35:201.
    PubMed     Text format    

  75. MILLIGAN P, Flach C, Theisen M
    Efficacy of the GMZ2 malaria vaccine in African children.
    Vaccine. 2017;35:202.
    PubMed     Text format    

  76. GRISEZ L, Frost P
    Efficacy and safety of an inactivated vaccine against Salmonid alphavirus (family Togaviridae) [Vaccine 30 (2012) 5688-5694].
    Vaccine. 2017;35:203.
    PubMed     Text format    

  77. KARLSEN M, Tingbo T, Solbakk IT, Furevik A, et al
    Response to request for Corrigendum to "Efficacy and safety of an inactivated vaccine against Salmonid alphavirus (family Togaviridae)". [Vaccine 30(38) (2012) 5688-5694].
    Vaccine. 2017;35:204.
    PubMed     Text format    

  78. CAMACHO A, Eggo RM, Goeyvaerts N, Vandebosch A, et al
    Real-time dynamic modelling for the design of a cluster-randomized phase 3 Ebola vaccine trial in Sierra Leone.
    Vaccine. 2016 Dec 23. pii: S0264-410X(16)31226.
    PubMed     Text format     Abstract available

  79. DOMNICH A, Arata L, Amicizia D, Puig-Barbera J, et al
    Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis.
    Vaccine. 2016 Dec 23. pii: S0264-410X(16)31218.
    PubMed     Text format     Abstract available

  80. LEE TY, Kim CU, Bae EH, Seo SH, et al
    Outer membrane vesicles harboring modified lipid A moiety augment the efficacy of an influenza vaccine exhibiting reduced endotoxicity in a mouse model.
    Vaccine. 2016 Dec 23. pii: S0264-410X(16)31232.
    PubMed     Text format     Abstract available

  81. LINDGREN LM, Tingskov PN, Justesen AH, Nedergaard BS, et al
    First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccin
    Vaccine. 2016 Dec 24. pii: S0264-410X(16)31234.
    PubMed     Text format     Abstract available

  82. PACE D, Khatami A, Attard-Montalto S, Voysey M, et al
    Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy.
    Vaccine. 2016 Oct 28. pii: S0264-410X(16)30973.
    PubMed     Text format     Abstract available

  83. PHELPS CE, Madhavan G, Gellin B
    Planning and priority setting for vaccine development and immunization.
    Vaccine. 2016 Dec 22. pii: S0264-410X(16)31057.
    PubMed     Text format     Abstract available

  84. MATTHIESSEN L, Lang H, Klimathianaki M, Hanrahan F, et al
    European strategy for vaccine development against infectious diseases.
    Vaccine. 2016 Dec 22. pii: S0264-410X(16)30952.
    PubMed     Text format     Abstract available

  85. POWELL AM, Luo Z, Martin L, Wan Z, et al
    The induction of CD80 and apoptosis on B cells and CD40L in CD4+ T cells in response to seasonal influenza vaccination distinguishes responders versus non-responders in healthy controls and aviremic ART-treated HIV-infected individuals.
    Vaccine. 2016 Dec 22. pii: S0264-410X(16)31233.
    PubMed     Text format     Abstract available

  86. LEE BY, Mueller LE, Tilchin CG
    A systems approach to vaccine decision making.
    Vaccine. 2016 Dec 22. pii: S0264-410X(16)31081.
    PubMed     Text format     Abstract available

  87. KOBAYASHI M, Schrag SJ, Alderson MR, Madhi SA, et al
    WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27-28 April 2016.
    Vaccine. 2016 Dec 22. pii: S0264-410X(16)31236.
    PubMed     Text format     Abstract available

  88. KNOBLER S, Bok K, Gellin B
    Informing vaccine decision-making: A strategic multi-attribute ranking tool for vaccines-SMART Vaccines 2.0.
    Vaccine. 2016 Dec 22. pii: S0264-410X(16)31060.
    PubMed     Text format     Abstract available

  89. BLOOM DE, Brenzel L, Cadarette D, Sullivan J, et al
    Moving beyond traditional valuation of vaccination: Needs and opportunities.
    Vaccine. 2016 Dec 22. pii: S0264-410X(16)31181.
    PubMed     Text format     Abstract available

  90. RAPPUOLI R
    Introduction to the vaccine supplement.
    Vaccine. 2016 Dec 22. pii: S0264-410X(16)31099.
    PubMed     Text format    

  91. KASLOW DC, Kalil J, Bloom D, Breghi G, et al
    The role of vaccines and vaccine decision-making to achieve the goals of the Grand Convergence in public health.
    Vaccine. 2016 Dec 22. pii: S0264-410X(16)31080.
    PubMed     Text format     Abstract available

  92. ALMOND J, Medaglini D
    The role of the vaccines industry in Mission Grand Convergence.
    Vaccine. 2016 Dec 22. pii: S0264-410X(16)31058.
    PubMed     Text format     Abstract available

  93. SOUTHERN J, Waight PA, Andrews N, Miller E, et al
    Extensive swelling of the limb and systemic symptoms after a fourth dose of acellular pertussis containing vaccines in England in children aged 3-6years.
    Vaccine. 2016 Dec 22. pii: S0264-410X(16)31224.
    PubMed     Text format     Abstract available

  94. SAUL A, O'Brien KL
    Prioritizing vaccines for developing world diseases.
    Vaccine. 2016 Dec 22. pii: S0264-410X(16)31062.
    PubMed     Text format     Abstract available

  95. RAMEZANPOUR B, Haan I, Osterhaus A, Claassen E, et al
    Vector-based genetically modified vaccines: Exploiting Jenner's legacy.
    Vaccine. 2016 Oct 28. pii: S0264-410X(16)30510.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: